GlassScriptPhysician profile
Kannika Green
NPI 1093334856
$11,416.72
in general payments reported to CMS, 2019-2025
54 companies · $2,917 in 2025
The $2,917 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.14 · 2022: $2,305 · 2023: $2,382 · 2024: $3,714 · 2025: $2,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,013.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,328.64 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,586.03 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,069.87 | 2022-2025 | |
| Amgen INC. | $958.88 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $787.65 | 2021-2025 | |
| Exact Sciences Corporation | $398.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $385.33 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $346.11 | 2021-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $297.72 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $261.56 | 2022 | |
| Pfizer INC. | $253.56 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.18 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.57 | 2022-2025 | Xifaxan |
| Neos Therapeutics, LP | $178.18 | 2022-2024 | Adzenys Xr-Odt |
| Antares Pharma, INC. | $170.12 | 2024-2025 | Xyosted |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $152.92 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.66 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $140.48 | 2024-2025 | Veozah |
| Ardelyx, INC. | $135.59 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $123.63 | 2022-2024 | Linzess |
| Xeris Pharmaceuticals, INC. | $122.63 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Intra-Sana Laboratories | $114.72 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Sanofi-Aventis U.S. LLC | $112.79 | 2025 | |
| Halozyme INC | $93.66 | 2023 | |
| Shield Therapeutics INC | $81.19 | 2022-2025 | Accrufer |
| Almatica Pharma LLC | $56.69 | 2023-2024 | Loreev Xr, Gralise |
| Hologic Sales and Service, LLC | $53.13 | 2022-2024 | Aptima |
| Corium, LLC | $51.63 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $47.53 | 2022-2023 | Quviviq |
| Beta Bionics, INC. | $45.91 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Collegium Pharmaceutical, INC. | $41.20 | 2022-2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $37.96 | 2022 | |
| Esperion Therapeutics, INC. | $32.95 | 2022 | |
| Boston Scientific Corporation | $27.16 | 2024 | |
| Supernus Pharmaceuticals, INC. | $24.66 | 2023 | Xyosted, Tlando, Qelbree |
| Regeneron Healthcare Solutions, INC. | $24.30 | 2023 | Evkeeza |
| Inari Medical, INC. | $21.13 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Siemens Medical Solutions USA, INC. | $21.00 | 2025 | Immulite 1000 Immunoassay System |
| Paratek Pharmaceuticals, INC. | $19.88 | 2022 | |
| Noven Therapeutics, LLC | $19.78 | 2024 | Xelstrym |
| Corcept Therapeutics | $18.65 | 2023 | Korlym |
| Verity Pharmaceuticals INC. | $18.60 | 2024 | Tlando |
| Tandem Diabetes Care, INC. | $17.75 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Axsome Therapeutics, INC. | $16.43 | 2023 | Auvelity |
| Genentech USA, INC. | $16.06 | 2021 | |
| Upsher-Smith Laboratories LLC | $14.85 | 2023 | |
| Merck Sharp & Dohme LLC | $14.77 | 2022 | |
| Currax Pharmaceuticals LLC | $14.56 | 2025 | Onzetra Xsail, Contrave |
| Medtronic, INC. | $14.26 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.25 | 2024 | |
| Vivus LLC | $13.68 | 2022 | |
| Tolmar, INC. | $13.63 | 2024 | |
| Nabriva Therapeutics, Plc | $12.83 | 2022 | |
| Tris Pharma INC | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kannika Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.